View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsValeo Pharma 将来の成長Future 基準チェック /26 Valeo Pharmaは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.7%収益成長率20.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日17 Jun 2024今後の成長に関する最新情報Breakeven Date Change • Feb 07No longer forecast to breakevenThe 2 analysts covering Valeo Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$13.5m in 2025. New consensus forecast suggests the company will make a loss of CA$12.4m in 2025.Breakeven Date Change • Jun 17Forecast breakeven date pushed back to 2025The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of CA$13.5m in 2025. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 16The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 54% to 2023. The company is expected to make a profit of CA$1.96m in 2024. Average annual earnings growth of 1.7% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesReported Earnings • Sep 14Third quarter 2024 earnings released: CA$0.083 loss per share (vs CA$0.069 loss in 3Q 2023)Third quarter 2024 results: CA$0.083 loss per share (further deteriorated from CA$0.069 loss in 3Q 2023). Revenue: CA$12.6m (down 11% from 3Q 2023). Net loss: CA$8.19m (loss widened 40% from 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Sep 09Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024Valeo Pharma Inc. announced that they will report Q3, 2024 results After-Market on Sep 12, 2024お知らせ • Aug 07Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced Mr. Steve Saviuk will remain on the company’s board of directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his role of chairman of the board and will remain a board member.お知らせ • Jun 18Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer (CDO) and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties with a view to strengthening the Company's capital structure in order to finance the future growth and development of the Company. He will work directly with the senior management team to plan, review, and revise the company's development programs. Mr. Moghaddam will also support the development and growth of the business through building relationships in the industry, identifying both product and M&A opportunities. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.New Risk • Jun 17New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$9.2m free cash flow). Share price has been highly volatile over the past 3 months (80% average daily change). Negative equity (-CA$55m). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (€7.38m market cap, or US$7.90m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).Reported Earnings • Jun 16Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023)Second quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jun 16Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023)Second quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.New Risk • Jun 14New major risk - Revenue and earnings growthEarnings have declined by 48% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Share price has been highly volatile over the past 3 months (80% average daily change). Negative equity (-CA$47m). Earnings have declined by 48% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$15m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€10.4m market cap, or US$11.1m).お知らせ • Jun 06Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024Valeo Pharma Inc. announced that they will report Q2, 2024 results After-Market on Jun 13, 2024New Risk • Apr 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.77m (US$9.45m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-CA$47m). Market cap is less than US$10m (€8.77m market cap, or US$9.45m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Mar 22Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has joined the Company's Board of Directors. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.Reported Earnings • Mar 15First quarter 2024 earnings released: CA$0.08 loss per share (vs CA$0.077 loss in 1Q 2023)First quarter 2024 results: CA$0.08 loss per share (further deteriorated from CA$0.077 loss in 1Q 2023). Revenue: CA$13.5m (up 2.9% from 1Q 2023). Net loss: CA$6.87m (loss widened 10.0% from 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 08Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024Valeo Pharma Inc. announced that they will report Q1, 2024 results After-Market on Mar 14, 2024お知らせ • Feb 27Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024.お知らせ • Feb 13Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. More about Robert Raich; Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years. His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning. Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences. More about Charles Bisaillon; Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company. Mr. Bisaillon graduated from l'École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).Breakeven Date Change • Feb 07No longer forecast to breakevenThe 2 analysts covering Valeo Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$13.5m in 2025. New consensus forecast suggests the company will make a loss of CA$12.4m in 2025.Reported Earnings • Jan 30Full year 2023 earnings released: CA$0.32 loss per share (vs CA$0.32 loss in FY 2022)Full year 2023 results: CA$0.32 loss per share (further deteriorated from CA$0.32 loss in FY 2022). Revenue: CA$53.9m (up 94% from FY 2022). Net loss: CA$27.8m (loss widened 8.0% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.お知らせ • Jan 23Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024Valeo Pharma Inc. announced that they will report Q4, 2023 results After-Market on Jan 29, 2024お知らせ • Nov 21Valeo Pharma Inc. Announces Chief Financial Officer ChangesValeo Pharma Inc. announced the appointment of Mr. Pascal Tougas to the position of Chief Financial Officer, effective November 20, 2023. Joining the Valeo leadership team, Mr. Tougas will succeed Luc Mainville, who is leaving the Company after 5 years to pursue other ventures. Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor's degree in business administration from the HEC Montreal and a CPA designation.お知らせ • Nov 08Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of DirectorsValeo Pharma Inc. announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors. ichard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams. Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals. Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.New Risk • Oct 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.41m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-CA$35m). Market cap is less than US$10m (€9.41m market cap, or US$9.99m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding).New Risk • Oct 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$28m Forecast net loss in 1 year: CA$17m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€11.3m market cap, or US$12.0m).Reported Earnings • Sep 14Third quarter 2023 earnings released: CA$0.069 loss per share (vs CA$0.058 loss in 3Q 2022)Third quarter 2023 results: CA$0.069 loss per share (further deteriorated from CA$0.058 loss in 3Q 2022). Revenue: CA$14.1m (up 132% from 3Q 2022). Net loss: CA$5.84m (loss widened 23% from 3Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.お知らせ • Sep 08Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023Valeo Pharma Inc. announced that they will report Q3, 2023 results After-Market on Sep 13, 2023お知らせ • Sep 01Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement QuébecValeo Pharma Inc. announced a non-brokered private placement of 13,999,997 units of the company at a price of CAD 0.28 per unit for gross proceeds of CAD 3,919,999 and entered into a loan agreement with a related party for a principal amount of CAD 580,000 bearing annual interest at a rate of 12%; for aggregate total gross proceeds of CAD 4,499,999 on August 31, 2023. The transaction included participation from Investissement Québec for CAD 2 million and insiders for CAD 1,421,000. Each unit consist of one class A share of the company and one-half share purchase warrant of the company. Each full warrant entitles the holder to purchase one share in the capital of the company at the price of CAD 0.35 per warrant share for a period of 60 months from the closing date of the transaction. In the event that the daily volume weighted average trading price of the shares over any ten consecutive trading days is greater or equal to CAD 0.70, the company may give notice to the warrant holder, at any time after the first 12 months following the closing, that all outstanding warrants must be exercised within a period of 30 days from the date of receipt of the notice, failing which the warrants will automatically expire. The common shares and the warrants are subject to a statutory 4 month hold period under the applicable securities laws.Board Change • Jun 29Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Marc Leger was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 23Valeo Pharma Inc. Announces Board AppointmentsValeo Pharma Inc. announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. Ms. Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy. She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker and regularly publishes ESG thought leadership and research. Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from McGill University and is a Chartered Financial Analyst (CFA). Mr. Didier Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. With a strong dedication to the development of Québec's and Canada's life sciences industries, Didier served as Vice-president, Life Science & Technology for Investissement Quebec and Vice-president Life Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA, Technology Management & Innovation from the Université du Québec à Montréal, a certification in governance from Université Laval and an engineering degree in Material Sciences from École d'ingénieurs Sup Galilée, Institut Galilée, Université Sorbonne Paris Nord.Breakeven Date Change • Jun 17Forecast breakeven date pushed back to 2025The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of CA$13.5m in 2025. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Reported Earnings • Jun 15Second quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.063 loss in 2Q 2022)Second quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.063 loss in 2Q 2022). Revenue: CA$13.6m (up 184% from 2Q 2022). Net loss: CA$6.48m (loss widened 27% from 2Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany.お知らせ • Jun 09Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023Valeo Pharma Inc. announced that they will report Q2, 2023 results After-Market on Jun 13, 2023Reported Earnings • Mar 17First quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.074 loss in 1Q 2022)First quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.074 loss in 1Q 2022). Revenue: CA$13.2m (up 210% from 1Q 2022). Net loss: CA$6.25m (loss widened 6.6% from 1Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany.Breakeven Date Change • Mar 16The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 54% to 2023. The company is expected to make a profit of CA$1.96m in 2024. Average annual earnings growth of 1.7% is required to achieve expected profit on schedule.お知らせ • Feb 08Valeo Pharma Obtains Public Reimbursement for Onstryv in QuebecValeo Pharma Inc. announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023. Onstryv® is approved by Health Canada as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's Disease in patients experiencing "off" episodes. Onstryvâ is a prescription medication available at pharmacies across Canada in 50mg and 100mg tablets. Parkinson's Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson's Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the higher incidences of Parkinson's Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases. Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a chemical entity with a unique mode of action including selective and reversible MAO-B inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity.Reported Earnings • Feb 01Full year 2022 earnings released: CA$0.32 loss per share (vs CA$0.20 loss in FY 2021)Full year 2022 results: CA$0.32 loss per share (further deteriorated from CA$0.20 loss in FY 2021). Revenue: CA$27.7m (up 105% from FY 2021). Net loss: CA$25.7m (loss widened 81% from FY 2021). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany.お知らせ • Jan 27Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 PatientsValeo Pharma Inc. announced that Health Canada has accepted for review Veru's New Drug Submission ("NDS-CV") for sabizabulin for COVID-19. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS) and death. The Phase 3 COVID-19 clinical trial of sabizabulin was a double-blind, randomized, placebo controlled trial conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID-19 (= WHO 4-supplemental oxygen) at high risk for ARDS and death. The primary endpoint was the proportion of deaths by Day 60. Patients in both treatment groups were allowed to receive standard of care treatment, including remdesivir, dexamethasone, anti-IL6 receptor antibodies and JAK inhibitors. Based on a planned interim analysis of the first 150 patients randomized, the Independent Data Monitoring Committee unanimously recommended to halt the study early for clear clinical efficacy and no safety concerns were identified. Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis were published in The New England Journal of Medicine (NEJM) Evidence. In the final analysis of all 204 patients, sabizabulin demonstrated a statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin was well tolerated. Valeo previously announced in September 2022 that Veru and Valeo had entered into an agreement under which Valeo is the commercial partner for Veru's product candidate sabizabulin for COVID-19 in Canada.お知らせ • Jan 26Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023Valeo Pharma Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 30, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 15Third quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.042 loss in 3Q 2021)Third quarter 2022 results: CA$0.058 loss per share (further deteriorated from CA$0.042 loss in 3Q 2021). Revenue: CA$6.07m (up 7.2% from 3Q 2021). Net loss: CA$4.74m (loss widened 60% from 3Q 2021). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany.Recent Insider Transactions • Jun 19Key Executive recently bought €83k worth of stockOn the 16th of June, Richard MacKay bought around 217k shares on-market at roughly €0.38 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €566k worth in shares.Reported Earnings • Jun 15Second quarter 2022 earnings released: CA$0.063 loss per share (vs CA$0.028 loss in 2Q 2021)Second quarter 2022 results: CA$0.063 loss per share (down from CA$0.028 loss in 2Q 2021). Revenue: CA$4.77m (up 80% from 2Q 2021). Net loss: CA$5.10m (loss widened 173% from 2Q 2021).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.20 loss per share (down from CA$0.082 loss in FY 2020). Revenue: CA$13.6m (up 82% from FY 2020). Net loss: CA$14.2m (loss widened 199% from FY 2020). Revenue missed analyst estimates by 7.1%. Over the next year, revenue is forecast to grow 174%, compared to a 4.1% growth forecast for the industry in Germany.Recent Insider Transactions • Oct 22Key Executive recently bought €63k worth of stockOn the 20th of October, Richard MacKay bought around 100k shares on-market at roughly €0.63 per share. In the last 3 months, they made an even bigger purchase worth €248k. Richard has been a buyer over the last 12 months, purchasing a net total of €483k worth in shares.Recent Insider Transactions • Oct 02Key Executive recently bought €53k worth of stockOn the 27th of September, Richard MacKay bought around 109k shares on-market at roughly €0.48 per share. In the last 3 months, there was an even bigger purchase from another insider worth €67k. Richard has been a buyer over the last 12 months, purchasing a net total of €121k worth in shares.Reported Earnings • Sep 23Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: CA$5.67m (up 280% from 3Q 2020). Net loss: CA$2.97m (loss widened 84% from 3Q 2020).Recent Insider Transactions • Jul 18Senior VP & CFO recently bought €67k worth of stockOn the 15th of July, Luc Mainville bought around 150k shares on-market at roughly €0.45 per share. In the last 3 months, they made an even bigger purchase worth €136k. Luc has been a buyer over the last 12 months, purchasing a net total of €214k worth in shares.Recent Insider Transactions • Jul 02Senior VP & CFO recently bought €136k worth of stockOn the 29th of June, Luc Mainville bought around 200k shares on-market at roughly €0.68 per share. This was the largest purchase by an insider in the last 3 months. Luc has been a buyer over the last 12 months, purchasing a net total of €146k worth in shares.Reported Earnings • Jul 01Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$2.65m (up 27% from 2Q 2020). Net loss: CA$1.87m (loss widened 117% from 2Q 2020).Recent Insider Transactions • Apr 21President recently bought €117k worth of stockOn the 15th of April, Frederic Fasano bought around 154k shares on-market at roughly €0.76 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of €132k worth in shares.Reported Earnings • Apr 02First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$1.86m (up 11% from 1Q 2020). Net loss: CA$1.73m (loss widened 56% from 1Q 2020).Reported Earnings • Feb 26Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$7.47m (up 14% from FY 2019). Net loss: CA$4.76m (loss widened 32% from FY 2019).Is New 90 Day High Low • Feb 25New 90-day low: €0.67The company is down 9.0% from its price of €0.73 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 10.0% over the same period.Is New 90 Day High Low • Jan 23New 90-day high: €0.94The company is up 57% from its price of €0.59 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 5.0% over the same period.お知らせ • Jan 20Valeo Pharma Appoints Frederic Fasano to the Newly Created Position of President and Chief Operating OfficerValeo Pharma Inc. announced the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo's commercial activities. Mr. Fasano has also been elected to the Company's Board of Directors effective as of January 18, 2021. In addition to continuing in his role as CEO of Valeo, Mr. Saviuk will assume the role of Vice-Chairman of Valeo's Board of Directors. Mr. Richard MacKay remains Chairman of the Board.Is New 90 Day High Low • Jan 06New 90-day high: €0.80The company is up 27% from its price of €0.63 on 08 October 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period.お知らせ • Dec 10Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™Valeo Pharma Inc. ("Valeo" or the "Company") announced that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin ("LMWH") biosimilars. In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization's ("WHO") issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected. The Company also announces that it has launched a 12-month digital investor awareness program through AGORACOM, a multifaceted digital platform operated by AGORA Internet Services Corp. ("AGORA"), in order to enhance information availability for current and future stakeholders. The Company has agreed to remunerate AGORA $75,000 plus taxes for the above mentioned services. A first service payment of $15,000 was made on December 7, 2020 with the remaining balance split equally and due on each of February 27, 2021, May 27, 2021, August 27, 2021, and December 31, 2021. Payment will be made through the issuance of the Company's common shares with the number of common shares to be issued determined by using the closing price on each date above. Common shares issued to AGORA under this agreement will be subject to a 4-month hold period.お知らせ • Nov 13Valeo Pharma Announces Amikacin Approval in Canada and U.S. Launch of Ethacrynate SodiumValeo Pharma Inc. announced that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of Ethacrynate Sodium have commenced in the U.S. market.お知らせ • Oct 14Valeo Pharma Announces That Hesperco™ Has Started ShippingValeo Pharma Inc. announced that it has commenced shipping online orders of its unique flavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that provides support for the immune system.Reported Earnings • Sep 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$4.81m, with losses widening by 45% from the prior year. Total revenue was CA$6.48m over the last 12 months, down 8.7% from the prior year.お知らせ • Sep 25Valeo Pharma Inc. to Report Q3, 2020 Results on Sep 29, 2020Valeo Pharma Inc. announced that they will report Q3, 2020 results on Sep 29, 2020お知らせ • Sep 11Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 6 million.Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,166,667 Price\Range: CAD 1.2 Discount Per Security: CAD 0.084 Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 833,333 Price\Range: CAD 1.2 Discount Per Security: CAD 0.03業績と収益の成長予測DB:VP2 - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数10/31/202570N/AN/AN/A110/31/202458N/AN/AN/A17/31/202453-32-7-4N/A4/30/202455-30-10-6N/A1/31/202454-28-8-3N/A10/31/202354-28-21-16N/A7/31/202353-28-20-24N/A4/30/202345-27-32-25N/A1/31/202337-26-37-31N/A10/31/202228-26-35-29N/A7/31/202218-24-33-20N/A4/30/202218-22-25-23N/A1/31/202216-18-22-19N/A10/31/202114-14-16-12N/A7/31/202112-9-14-12N/A4/30/20218-7-10-7N/A1/31/20218-5-8-6N/A10/31/20207-5-7-5N/A7/31/20207-4-5-4N/A4/30/20208-2-5-4N/A1/31/20206-4-5-4N/A10/31/20197-4-3-2N/A7/31/20197-3-3-2N/A4/30/20197-3-2-2N/A1/31/20196-3-2-1N/A10/31/20184-2-2-1N/A7/31/20183-3-1-1N/A10/31/20171-4N/A-1N/A10/31/20161-1N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VP2の予測収益成長が 貯蓄率 ( 1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VP2の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VP2の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VP2の収益 ( 20.9% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: VP2の収益 ( 20.9% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VP2の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/11/21 17:44終値2024/10/02 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Valeo Pharma Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Scott McAuleyParadigm Capital, Inc.
Breakeven Date Change • Feb 07No longer forecast to breakevenThe 2 analysts covering Valeo Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$13.5m in 2025. New consensus forecast suggests the company will make a loss of CA$12.4m in 2025.
Breakeven Date Change • Jun 17Forecast breakeven date pushed back to 2025The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of CA$13.5m in 2025. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 16The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 54% to 2023. The company is expected to make a profit of CA$1.96m in 2024. Average annual earnings growth of 1.7% is required to achieve expected profit on schedule.
Reported Earnings • Sep 14Third quarter 2024 earnings released: CA$0.083 loss per share (vs CA$0.069 loss in 3Q 2023)Third quarter 2024 results: CA$0.083 loss per share (further deteriorated from CA$0.069 loss in 3Q 2023). Revenue: CA$12.6m (down 11% from 3Q 2023). Net loss: CA$8.19m (loss widened 40% from 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Sep 09Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024Valeo Pharma Inc. announced that they will report Q3, 2024 results After-Market on Sep 12, 2024
お知らせ • Aug 07Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced Mr. Steve Saviuk will remain on the company’s board of directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his role of chairman of the board and will remain a board member.
お知らせ • Jun 18Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer (CDO) and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of strategies to identify and negotiate with financial parties with a view to strengthening the Company's capital structure in order to finance the future growth and development of the Company. He will work directly with the senior management team to plan, review, and revise the company's development programs. Mr. Moghaddam will also support the development and growth of the business through building relationships in the industry, identifying both product and M&A opportunities. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.
New Risk • Jun 17New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$9.2m free cash flow). Share price has been highly volatile over the past 3 months (80% average daily change). Negative equity (-CA$55m). Earnings have declined by 44% per year over the past 5 years. Market cap is less than US$10m (€7.38m market cap, or US$7.90m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
Reported Earnings • Jun 16Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023)Second quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jun 16Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023)Second quarter 2024 results: CA$0.079 loss per share (further deteriorated from CA$0.077 loss in 2Q 2023). Revenue: CA$14.1m (up 4.2% from 2Q 2023). Net loss: CA$7.81m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
New Risk • Jun 14New major risk - Revenue and earnings growthEarnings have declined by 48% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Share price has been highly volatile over the past 3 months (80% average daily change). Negative equity (-CA$47m). Earnings have declined by 48% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$15m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€10.4m market cap, or US$11.1m).
お知らせ • Jun 06Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024Valeo Pharma Inc. announced that they will report Q2, 2024 results After-Market on Jun 13, 2024
New Risk • Apr 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.77m (US$9.45m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$8.1m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-CA$47m). Market cap is less than US$10m (€8.77m market cap, or US$9.45m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Mar 22Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of DirectorsValeo Pharma Inc. announced that Mr. Al Moghaddam has joined the Company's Board of Directors. Mr. Moghaddam is a customer centric transformational life sciences leader with over 25 years of global experience. His work experience spans from large multinationals through to early-stage companies and he has held leadership positions within pharma, medical device, med-tech, and consumer markets. He is a strong visionary, process driven leader, able to craft a vision and motivate teams to achieve superior results and recognized by such companies as Allergan, Bristol Myers Squibb, Teva & Pharmascience for outstanding performance in creating value. Al has cross functional experience in product life cycle management, sales, BD&L, market access, marketing, finance & M&A.
Reported Earnings • Mar 15First quarter 2024 earnings released: CA$0.08 loss per share (vs CA$0.077 loss in 1Q 2023)First quarter 2024 results: CA$0.08 loss per share (further deteriorated from CA$0.077 loss in 1Q 2023). Revenue: CA$13.5m (up 2.9% from 1Q 2023). Net loss: CA$6.87m (loss widened 10.0% from 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 08Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024Valeo Pharma Inc. announced that they will report Q1, 2024 results After-Market on Mar 14, 2024
お知らせ • Feb 27Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024.
お知らせ • Feb 13Valeo Pharma Inc. Announces Board ChangesValeo Pharma Inc. announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. More about Robert Raich; Prior to establishing RaichLegal Inc, Robert Raich was a senior partner at Spiegel Sohmer Inc., a Montreal firm specializing in taxation law, where he served as managing partner for over 25 years. His areas of expertise include taxation advice for real estate transactions, advice to both purchasers and vendors in acquisitions and sales of businesses, corporate reorganizations, venture capital financing and charitable planning. Mr. Raich graduated from McGill University and was called to the Barreau du Quebec in 1976. He has been recognized on several occasions as one of the Best Lawyers in Canada in the fields of Taxation law and Law of Estates and Trusts in Canada and has been a frequent guest lecturer at McGill University Faculty of Law and tax conferences. More about Charles Bisaillon; Charles Bisaillon is an entrepreneurial-minded leader who loves rapidly scaling organizations in both wholesale & direct-to-consumer channels. Charles is currently President and owner of Airtek Ltée, a leading Canadian manufacturing company, established in Montreal Quebec since 1970. Charles is also the Chief Financial Officer Groupe J.B a residential, commercial & institutional construction company. Mr. Bisaillon graduated from l'École des sciences de la gestion, UQAM. He is a chartered professional accountant of Canada (CPA Canada).
Breakeven Date Change • Feb 07No longer forecast to breakevenThe 2 analysts covering Valeo Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CA$13.5m in 2025. New consensus forecast suggests the company will make a loss of CA$12.4m in 2025.
Reported Earnings • Jan 30Full year 2023 earnings released: CA$0.32 loss per share (vs CA$0.32 loss in FY 2022)Full year 2023 results: CA$0.32 loss per share (further deteriorated from CA$0.32 loss in FY 2022). Revenue: CA$53.9m (up 94% from FY 2022). Net loss: CA$27.8m (loss widened 8.0% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 23Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024Valeo Pharma Inc. announced that they will report Q4, 2023 results After-Market on Jan 29, 2024
お知らせ • Nov 21Valeo Pharma Inc. Announces Chief Financial Officer ChangesValeo Pharma Inc. announced the appointment of Mr. Pascal Tougas to the position of Chief Financial Officer, effective November 20, 2023. Joining the Valeo leadership team, Mr. Tougas will succeed Luc Mainville, who is leaving the Company after 5 years to pursue other ventures. Pascal is a seasoned senior pharmaceutical executive with a strong finance profile. With a passion for driving value in organizations, Pascal has a track record of collaboration, forward strategic thinking, operational and financial business acumen, and execution. Pascal spent 11 years at Sanofi Canada in roles of increasing responsibility where he served as Country Head, Trade and Revenue Management, Chief Financial Officer Canada interim and Director Controlling and Operations Canada amongst others. Pascal holds a bachelor's degree in business administration from the HEC Montreal and a CPA designation.
お知らせ • Nov 08Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of DirectorsValeo Pharma Inc. announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors. ichard Lajoie has been recognized over the last 24 years as an inspirational and creative leader with a strong capacity to build high performing teams. Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted to President Ortho Dermatologics US based in New Jersey. He has led innovative business model transformations, many new launches and completed successful business development deals. Prior to Bausch Health, Richard spent 12 years with Novartis Pharmaceuticals in roles of increasing responsibility (Sales, Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis Oncology.
New Risk • Oct 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.41m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-CA$35m). Market cap is less than US$10m (€9.41m market cap, or US$9.99m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding).
New Risk • Oct 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$28m Forecast net loss in 1 year: CA$17m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$17m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€11.3m market cap, or US$12.0m).
Reported Earnings • Sep 14Third quarter 2023 earnings released: CA$0.069 loss per share (vs CA$0.058 loss in 3Q 2022)Third quarter 2023 results: CA$0.069 loss per share (further deteriorated from CA$0.058 loss in 3Q 2022). Revenue: CA$14.1m (up 132% from 3Q 2022). Net loss: CA$5.84m (loss widened 23% from 3Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 08Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023Valeo Pharma Inc. announced that they will report Q3, 2023 results After-Market on Sep 13, 2023
お知らせ • Sep 01Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement QuébecValeo Pharma Inc. announced a non-brokered private placement of 13,999,997 units of the company at a price of CAD 0.28 per unit for gross proceeds of CAD 3,919,999 and entered into a loan agreement with a related party for a principal amount of CAD 580,000 bearing annual interest at a rate of 12%; for aggregate total gross proceeds of CAD 4,499,999 on August 31, 2023. The transaction included participation from Investissement Québec for CAD 2 million and insiders for CAD 1,421,000. Each unit consist of one class A share of the company and one-half share purchase warrant of the company. Each full warrant entitles the holder to purchase one share in the capital of the company at the price of CAD 0.35 per warrant share for a period of 60 months from the closing date of the transaction. In the event that the daily volume weighted average trading price of the shares over any ten consecutive trading days is greater or equal to CAD 0.70, the company may give notice to the warrant holder, at any time after the first 12 months following the closing, that all outstanding warrants must be exercised within a period of 30 days from the date of receipt of the notice, failing which the warrants will automatically expire. The common shares and the warrants are subject to a statutory 4 month hold period under the applicable securities laws.
Board Change • Jun 29Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Marc Leger was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 23Valeo Pharma Inc. Announces Board AppointmentsValeo Pharma Inc. announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. Ms. Close is a senior investment and Environmental, Social and Governance (ESG) professional with over 25 years of experience in capital markets, with roles spanning sell-side trading and institutional sales to buy-side research, risk management and strategy. She is the founder and managing partner of Close Group Consulting, an independent, boutique ESG advisory firm headquartered in Montreal, with offices in Toronto, Boston, and London (UK). Tamara is a sought-after speaker and regularly publishes ESG thought leadership and research. Ms. Close holds an M.Sc. Finance from Concordia University with a B.A. Economics from McGill University and is a Chartered Financial Analyst (CFA). Mr. Didier Leconte is a highly experienced investor and Canadian life sciences leader. He has deep commercial experience in Canada and Québec's technology transfer and investment arenas. With a strong dedication to the development of Québec's and Canada's life sciences industries, Didier served as Vice-president, Life Science & Technology for Investissement Quebec and Vice-president Life Sciences at Fonds de solidarité FTQ. Mr. Leconte holds a MBA, Technology Management & Innovation from the Université du Québec à Montréal, a certification in governance from Université Laval and an engineering degree in Material Sciences from École d'ingénieurs Sup Galilée, Institut Galilée, Université Sorbonne Paris Nord.
Breakeven Date Change • Jun 17Forecast breakeven date pushed back to 2025The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of CA$13.5m in 2025. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Reported Earnings • Jun 15Second quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.063 loss in 2Q 2022)Second quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.063 loss in 2Q 2022). Revenue: CA$13.6m (up 184% from 2Q 2022). Net loss: CA$6.48m (loss widened 27% from 2Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany.
お知らせ • Jun 09Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023Valeo Pharma Inc. announced that they will report Q2, 2023 results After-Market on Jun 13, 2023
Reported Earnings • Mar 17First quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.074 loss in 1Q 2022)First quarter 2023 results: CA$0.077 loss per share (further deteriorated from CA$0.074 loss in 1Q 2022). Revenue: CA$13.2m (up 210% from 1Q 2022). Net loss: CA$6.25m (loss widened 6.6% from 1Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany.
Breakeven Date Change • Mar 16The 4 analysts covering Valeo Pharma previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 54% to 2023. The company is expected to make a profit of CA$1.96m in 2024. Average annual earnings growth of 1.7% is required to achieve expected profit on schedule.
お知らせ • Feb 08Valeo Pharma Obtains Public Reimbursement for Onstryv in QuebecValeo Pharma Inc. announced that Onstryv (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023. Onstryv® is approved by Health Canada as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's Disease in patients experiencing "off" episodes. Onstryvâ is a prescription medication available at pharmacies across Canada in 50mg and 100mg tablets. Parkinson's Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson's Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the higher incidences of Parkinson's Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases. Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world, is a chemical entity with a unique mode of action including selective and reversible MAO-B inhibition. Clinical trials have established its efficacy in controlling motor symptoms and motor complications in the short term, maintaining this effect over 2 years. Results from 24 month double-blind controlled studies suggest that safinamide shows statistically significant effects on motor fluctuations (ON/OFF time) without increasing the risk of developing troublesome dyskinesia. Onstryv® is a once-daily dose and has no diet restrictions due to its high MAO-B/MAO-A selectivity.
Reported Earnings • Feb 01Full year 2022 earnings released: CA$0.32 loss per share (vs CA$0.20 loss in FY 2021)Full year 2022 results: CA$0.32 loss per share (further deteriorated from CA$0.20 loss in FY 2021). Revenue: CA$27.7m (up 105% from FY 2021). Net loss: CA$25.7m (loss widened 81% from FY 2021). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany.
お知らせ • Jan 27Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 PatientsValeo Pharma Inc. announced that Health Canada has accepted for review Veru's New Drug Submission ("NDS-CV") for sabizabulin for COVID-19. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being developed for the treatment of hospitalized moderate to severe COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS) and death. The Phase 3 COVID-19 clinical trial of sabizabulin was a double-blind, randomized, placebo controlled trial conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID-19 (= WHO 4-supplemental oxygen) at high risk for ARDS and death. The primary endpoint was the proportion of deaths by Day 60. Patients in both treatment groups were allowed to receive standard of care treatment, including remdesivir, dexamethasone, anti-IL6 receptor antibodies and JAK inhibitors. Based on a planned interim analysis of the first 150 patients randomized, the Independent Data Monitoring Committee unanimously recommended to halt the study early for clear clinical efficacy and no safety concerns were identified. Treatment with sabizabulin 9 mg once daily, an oral, first-in-class, new chemical entity, microtubule disruptor that has dual anti-inflammatory and antiviral properties, resulted in a clinically meaningful and statistically significant 55.2% relative reduction in deaths compared to placebo. The results of the interim analysis were published in The New England Journal of Medicine (NEJM) Evidence. In the final analysis of all 204 patients, sabizabulin demonstrated a statistically significant 51.6% relative reduction in deaths compared to placebo. Sabizabulin was well tolerated. Valeo previously announced in September 2022 that Veru and Valeo had entered into an agreement under which Valeo is the commercial partner for Veru's product candidate sabizabulin for COVID-19 in Canada.
お知らせ • Jan 26Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023Valeo Pharma Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 30, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 15Third quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.042 loss in 3Q 2021)Third quarter 2022 results: CA$0.058 loss per share (further deteriorated from CA$0.042 loss in 3Q 2021). Revenue: CA$6.07m (up 7.2% from 3Q 2021). Net loss: CA$4.74m (loss widened 60% from 3Q 2021). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany.
Recent Insider Transactions • Jun 19Key Executive recently bought €83k worth of stockOn the 16th of June, Richard MacKay bought around 217k shares on-market at roughly €0.38 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of €566k worth in shares.
Reported Earnings • Jun 15Second quarter 2022 earnings released: CA$0.063 loss per share (vs CA$0.028 loss in 2Q 2021)Second quarter 2022 results: CA$0.063 loss per share (down from CA$0.028 loss in 2Q 2021). Revenue: CA$4.77m (up 80% from 2Q 2021). Net loss: CA$5.10m (loss widened 173% from 2Q 2021).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Michel Trudeau was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 02Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: CA$0.20 loss per share (down from CA$0.082 loss in FY 2020). Revenue: CA$13.6m (up 82% from FY 2020). Net loss: CA$14.2m (loss widened 199% from FY 2020). Revenue missed analyst estimates by 7.1%. Over the next year, revenue is forecast to grow 174%, compared to a 4.1% growth forecast for the industry in Germany.
Recent Insider Transactions • Oct 22Key Executive recently bought €63k worth of stockOn the 20th of October, Richard MacKay bought around 100k shares on-market at roughly €0.63 per share. In the last 3 months, they made an even bigger purchase worth €248k. Richard has been a buyer over the last 12 months, purchasing a net total of €483k worth in shares.
Recent Insider Transactions • Oct 02Key Executive recently bought €53k worth of stockOn the 27th of September, Richard MacKay bought around 109k shares on-market at roughly €0.48 per share. In the last 3 months, there was an even bigger purchase from another insider worth €67k. Richard has been a buyer over the last 12 months, purchasing a net total of €121k worth in shares.
Reported Earnings • Sep 23Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: CA$5.67m (up 280% from 3Q 2020). Net loss: CA$2.97m (loss widened 84% from 3Q 2020).
Recent Insider Transactions • Jul 18Senior VP & CFO recently bought €67k worth of stockOn the 15th of July, Luc Mainville bought around 150k shares on-market at roughly €0.45 per share. In the last 3 months, they made an even bigger purchase worth €136k. Luc has been a buyer over the last 12 months, purchasing a net total of €214k worth in shares.
Recent Insider Transactions • Jul 02Senior VP & CFO recently bought €136k worth of stockOn the 29th of June, Luc Mainville bought around 200k shares on-market at roughly €0.68 per share. This was the largest purchase by an insider in the last 3 months. Luc has been a buyer over the last 12 months, purchasing a net total of €146k worth in shares.
Reported Earnings • Jul 01Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$2.65m (up 27% from 2Q 2020). Net loss: CA$1.87m (loss widened 117% from 2Q 2020).
Recent Insider Transactions • Apr 21President recently bought €117k worth of stockOn the 15th of April, Frederic Fasano bought around 154k shares on-market at roughly €0.76 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of €132k worth in shares.
Reported Earnings • Apr 02First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$1.86m (up 11% from 1Q 2020). Net loss: CA$1.73m (loss widened 56% from 1Q 2020).
Reported Earnings • Feb 26Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: CA$7.47m (up 14% from FY 2019). Net loss: CA$4.76m (loss widened 32% from FY 2019).
Is New 90 Day High Low • Feb 25New 90-day low: €0.67The company is down 9.0% from its price of €0.73 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 10.0% over the same period.
Is New 90 Day High Low • Jan 23New 90-day high: €0.94The company is up 57% from its price of €0.59 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 5.0% over the same period.
お知らせ • Jan 20Valeo Pharma Appoints Frederic Fasano to the Newly Created Position of President and Chief Operating OfficerValeo Pharma Inc. announced the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo's commercial activities. Mr. Fasano has also been elected to the Company's Board of Directors effective as of January 18, 2021. In addition to continuing in his role as CEO of Valeo, Mr. Saviuk will assume the role of Vice-Chairman of Valeo's Board of Directors. Mr. Richard MacKay remains Chairman of the Board.
Is New 90 Day High Low • Jan 06New 90-day high: €0.80The company is up 27% from its price of €0.63 on 08 October 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period.
お知らせ • Dec 10Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™Valeo Pharma Inc. ("Valeo" or the "Company") announced that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin ("LMWH") biosimilars. In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization's ("WHO") issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected. The Company also announces that it has launched a 12-month digital investor awareness program through AGORACOM, a multifaceted digital platform operated by AGORA Internet Services Corp. ("AGORA"), in order to enhance information availability for current and future stakeholders. The Company has agreed to remunerate AGORA $75,000 plus taxes for the above mentioned services. A first service payment of $15,000 was made on December 7, 2020 with the remaining balance split equally and due on each of February 27, 2021, May 27, 2021, August 27, 2021, and December 31, 2021. Payment will be made through the issuance of the Company's common shares with the number of common shares to be issued determined by using the closing price on each date above. Common shares issued to AGORA under this agreement will be subject to a 4-month hold period.
お知らせ • Nov 13Valeo Pharma Announces Amikacin Approval in Canada and U.S. Launch of Ethacrynate SodiumValeo Pharma Inc. announced that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of Ethacrynate Sodium have commenced in the U.S. market.
お知らせ • Oct 14Valeo Pharma Announces That Hesperco™ Has Started ShippingValeo Pharma Inc. announced that it has commenced shipping online orders of its unique flavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that provides support for the immune system.
Reported Earnings • Sep 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CA$4.81m, with losses widening by 45% from the prior year. Total revenue was CA$6.48m over the last 12 months, down 8.7% from the prior year.
お知らせ • Sep 25Valeo Pharma Inc. to Report Q3, 2020 Results on Sep 29, 2020Valeo Pharma Inc. announced that they will report Q3, 2020 results on Sep 29, 2020
お知らせ • Sep 11Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 6 million.Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,166,667 Price\Range: CAD 1.2 Discount Per Security: CAD 0.084 Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 833,333 Price\Range: CAD 1.2 Discount Per Security: CAD 0.03